Approvals, Policy Changes Raise Profile of Biosimilars in Canada
At least 8 biosimilars were approved in Canada over the past 12 months, as policy makers made a strong push for biosimilar acceptance, which led to a change in prescribing patterns.
No Easy Path to Market for Alvotech's Adalimumab Biosimilar
In hopes of protecting its lucrative adalimumab (Humira) franchise, AbbVie is mounting a hefty legal defense against Alvotech's adalimumab biosimilar candidate.
Findings Are Reported From De-escalation Therapy in Early Breast Cancer
Investigators said pathologic complete response was higher with a molecularly selected subgroup of patients with early-stage breast cancer treated with a nonchemotherapy combination that included a trastuzumab biosimilar.
Surveys Probe Biosimilars in Oncology
Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.
Investigators Estimate Cost of Extending HER2-Directed Therapy With Biosimilars in British Columbia
Costs of extending human epidermal growth factor receptor 2 (HER2) therapy for patients with metastatic breast cancer were estimated in a retrospective study.
Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer
Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.
Field of Potential Adalimumab Biosimilar Contenders Continues to Grow
The list of potential adalimumab biosimilars has now lengthened to 10, according to a Cardinal Health summary of these products and their distinguishing features.
Proponents of Uniform Billing Codes for Biosimilars Cite Generic Savings Success
Generics and biosimilars are reimbursed differently, causing providers to prefer lower-cost generics and higher-priced biologics, authors of a study and opinion piece contend.
EMA and WHO "Tailor" the Biosimilar Development Process
The European Medicines Agency (EMA) reports on progress to create a smoother, less wasteful biosimilar development process; and the World Health Organization (WHO) revises its biosimilar development guidelines.
AAM Panel of Manufacturers Says Drug Price Rebates Must Go
Sandoz, Lupin, and Biocon Biologics representatives at the Association for Accessible Medicines (AAM) GRx+Biosims conference said that drug price rebates hinder biosimilar competition.
COA Reports Improved Biosimilar Access in Oncology
For trastuzumab and bevacizumab, biosimilars now represent a high share of administrations, but payer policies still hinder uptake of these products, the Community Oncology Alliance (COA) reports.
Pathologists Discuss Actionable Mutations and Testing in Metastatic Breast Cancer
Genetic profiling in recurrent and advanced breast cancer can yield actionable, smoking-gun biomarkers, Stanford Cancer Institute pathologists explained at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors.
Biosimilar Interchangeability: What's in a Name?
There is now a mad scramble to gain interchangeable status for biosimilars, but the meaning and significance of this appellation haven't yet been worked out for health care consumers or the manufacturing community.
FDA Deputy Director Discusses Initiatives to Advance Biosimilar Use
An overview of activities at the FDA to promote the use of biosimilars was presented by Jacqueline Corrigan-Curay, JD, MD, principal deputy center director for the Center for Drug Evaluation and Research (CDER) at the FDA.
Review Recommends Options for Pediatric Treatment of Clostridioides difficile Infection
Evidence is insubstantial for treatment of Clostridioides difficile infection (CDI), but authors of a review of available evidence provide recommendations for agents and testing.
Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
Pharmacy experts from IPD Analytics explained the potential for authorized biologics, which would compete, potentially on the same price footing, with biosimilars.
Investigators Elucidate Outcomes and Costs in CDI
In studies presented at the American College of Gastroenterology 2021 meeting, success was reported for RBX2660, a treatment for clostridioides difficile infection (CDI).
Surveys on Biosimilar Awareness and Acceptance Reported at AMCP Nexus 2021
Education is needed for both patients and pharmacists to ensure appropriate understanding, investigators reported at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021 meeting.
AMCP Studies Highlight Workplace Costs of Skin Care
Studies presented at Academy of Managed Care Pharmacy Nexus 2021 elucidated costs of skin treatment for workers in terms of recovery time taken and percentage of salary.
Study: PET/CT Scans Predict for Response in Salvage-Stage DLBCL
For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.
A Review of Standard of Care in DLBCL
A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.
FDA Approves Insulin Glargine as Country’s First Interchangeable Biosimilar
The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician.
Speakers Suggest Moving Newer Agents Into Earlier Lines in MM
Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.
Investigators Report Survival, Cost-effectiveness Data for Zanubrutinb
Using limited data from the ASPEN trial, investigators estimated survival probability and cost-effectiveness for zanubrutinib vs other agents in Waldenström macroglobulinemia.
Treatment for CML Is Unclear in Later Stages of Disease
There are many unknowns for third-line chronic myeloid leukemia (CML) treatment and beyond, speakers said at the EHA2021 Virtual Congress.
Mandatory Biosimilar Switching Pays Off for Canada
For Alberta and Green Shield Canada, savings are beginning to add up from switching initiatives for multiple reference biologics.
Study Supports Off-label Use of Infliximab Biosimilar in HS
Hidradenitis suppurativa (HS) is a difficult-to-treat skin condition that has responded to infliximab, although payer support in this setting is often lacking.
Biosimilars Advance in the Oncology Space
Hospital reimbursement deals slow the adoption of biosimilars in oncology, but cost concerns contribute to the incentives to use these agents.
Choice Is Vital to Biosimilar Savings Picture, Panelists Say
The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.
New Zealand Study Reveals Importance of Patient Attitudes Toward Biosimilars
Patients who research medical information online are likely to be more concerned about switching from originator products to biosimilars, according to the study.
2 Clarke Drive Cranbury, NJ 08512